Uptake of biosimilars on the rise in the US, but number of marketed products lags other countries

Fewer biosimilars have been marketed in the United States, compared with Germany and Switzerland, and prices are significantly higher in the US. However, biosimilars that have been introduced in the US recently had a stronger uptake than products that came on the market earlier.